Suzanne Day

Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial

Sonya Abraham, Helene Bæk Juel, Peter Fibiger Bang et al. · The Lancet Infectious Diseases · 2019 · 190 citations

Vaccination, Mucosal Vaccination, Caf01 Liposomes +4

Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial

Katrina M. Pollock, Hannah M. Cheeseman, Alexander J. Szubert et al. · EClinicalMedicine · 2022 · 149 citations · Full text

The role of helper lipids in optimising nanoparticle formulations of self-amplifying RNA

Beatriz Dias Barbieri, David J. Peeler, Karnyart Samnuan et al. · Journal of Controlled Release · 2024 · 39 citations · Full text

Nanoparticles, Nanotherapeutics, Engineering +21

Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies

Casey Williams, Suzanne Day, Michael D. Reed et al. · Biology of Blood and Marrow Transplantation · 2004 · 31 citations · Full text

An investigation of trachoma vaccine regimens by the chlamydia vaccine CTH522 administered with cationic liposomes in healthy adults (CHLM-02): a phase 1, double-blind trial

Katrina M. Pollock, Álvaro H. Borges, Hannah M. Cheeseman et al. · The Lancet Infectious Diseases · 2024 · 29 citations · Full text

Vaccination, Chlamydia Vaccine Cth522, Mucosal Vaccination +6